Retina Center of New Jersey

Bloomfield, New Jersey 07003

1 studies enrolling now · 11 studies all time

What they study most

DME, Diabetic Macular Edema, Diabetic Macular Edema (DME), Geographic Atrophy, Geographic Atrophy of the Macula, Macular Degeneration, Macular Edema Secondary to Retinal Vein Occlusion, Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD), Neovascular Age-related Macular Degeneration, Nonproliferative Diabetic Retinopathy

Studies at this site

• CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME — Recruiting now
• A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) — Completed
• A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) — Running, not enrolling
• Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration — Running, not enrolling
• Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye — Completed
• The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) — Completed
• Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration — Completed
• A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema — Completed
• Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD — Completed
• A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) — Stopped early